Everything below concerns GHRH analog. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
(2008); "Molecular Dynamics Simulation Methods including Quantum Effects"; In: Solvation Effects on Molecules and Biomolecules, Canuto, Sylvio (Eds.), ISBN 978-1-4020-8269-6, Springer, Heidelberg 2008, pp. 247–278. Rode, Bernd M.; Hofer, Thomas S.; Pribil, Andreas B.; Randolf, Bernhard R. (2010); "Simulations of Liquids and Solutions Based on Quantum Mechanical Forces"; In: Theoretical and Computational Inorganic Chemistry, van Eldik, Rudi; Harvey, Jeremy (Eds.), ISBN 978-0-12-380874-5, Elsevier, Amsterdam 2010, pp. 143–175. Hofer, Thomas S.; Pribil, Andreas B.; Randolf, Bernhard R.; Rode, Bernd M.; "Ab Initio Quantum Mechanical Charge Field Molecular Dynamics - A Nonparametrized First-Principle Approach to Liquids and Solutions"; In: Advances in Quantum Chemistry, Sabin, John R.; Brändas, Erkki (Eds.), ISBN 978-0-12-380898-1, Elsevier, Amsterdam 2010, 213–246. Jakschitz, Thomas; Fitz, Daniel; Rode, Bernd Michael (2012); "The origin of first peptides on earth: from amino acids to homochiral biomolecules"; In: Genesis - In The Beginning, Joseph Seckbach (Edp.), ISBN 978-94-007-2940-7, Springer, Dordrecht 2012, pp. 469–489. Lutz, Oliver M. D.; Messner, Christoph B.; Hofer, Thomas S.; Glätzle, Matthias; Huck, Christian W.; Bonn, Günther K.; Rode, Bernd M.; "Combined Ab Initio Computational and Infrared Spectroscopic Study of the cis- and trans-Bis(glycinato)copper(II) Complexes in Aqueous Environment"; J. Phys. Chem. Lett. 2013, 4, p. 1502-1506. DOI: 10.1021/jz400288c. Schwendinger, M. G.; Rode, Bend M.
Nanohedron.com images of nanoparticles Lectures on All Phases of Nanoparticle Science and Technology Archived 29 August 2010 at the Wayback Machine ENPRA – Risk Assessment of Engineered NanoParticles EC FP7 Project led by the Institute of Occupational Medicine
Federal intervention in state affairs, lack of development, and disputes over oil royalties have occasionally led to statements about secession from leaders in several states such as Penang, Johor, Kelantan, Sabah and Sarawak, although these have not been followed up and no serious independence movements exist.
Steel belts are generally made from carbon steel or stainless steel which has been alloyed or treated depending on the application. Compared to plastic belts, steel belts are generally more expensive upfront, but it can offer better durability. Over time, a steel belt may develop deformations or curvature due to wear and tear. These deformations can be rectified through various methods such as shot peening to flatten out the cross curvature of deformed steel belts. This process can be performed on-site without interrupting production. The two main systems using steel belts are single-belt and double-belt systems. Single-belt systems are appropriate for manufacturing single-sided products such as pastilles, flakes, strips, and sheets. The double-belt system can manufacture the top and bottom of a product simultaneously, such as in chemical, rubber, laminate, and composite material processing operations.
Nuclide column Nuclide identifiers are given by their atomic mass number A and the symbol for the corresponding chemical element (corresponding to the unique proton number). In the cases that this is not the ground state, this is indicated by a m for metastable appended to the mass number; the conventional numbers are further appended to distinguish multiple metastable states but '1' is omitted if the others are much less stable.
Sources: en.wikipedia.org
Support for teens (archive) University of Maryland guide to puberty and adolescence Growing Up Sexually: A World Atlas Pictures and detailed information about breast development during puberty Puberty in females: interactive animation of Tanner stages Puberty in males: interactive animation of Tanner stages
=== Judiciary === The judicial system was a typical hierarchical structure consisting of lower courts, a High Court and a Court of Appeal. Successive chief justices were Sir Stafford Foster-Sutton (1950–1951) (afterwards Chief Justice of Nigeria, 1955), Sir Charles Mathew (1951–1956) and Sir James Beveridge Thomson (1957–1963).
=== Stocking === Research from the late 1800s to the 1980s suggests a trend of intentional stockings of nonindigenous fish into ponds, lakes, and rivers in the United States. At that time, little was known about environmental impacts or long-term effects of new species establishment and spread as a result of "fish rescue and transfer" efforts, or the importance of nongame fish to the ecological balance of aquatic ecosystems. Introductions of bowfin to areas they were considered a nonindigenous species included various lakes, rivers, and drainages in Connecticut, Delaware, Georgia, Illinois, Iowa, Kansas, Kentucky, Maryland, Massachusetts, Minnesota, Missouri, New Jersey, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, Virginia, West Virginia, and Wisconsin. Many of the introductions were intentional stockings, positively determining distribution resulting from flood transfers, or other inadvertent migrations is not possible. Bowfin are typically piscivorous, but as an introduced species, they are capable of being voracious predators that pose a threat to native fish and their prey.
=== Proteins forming amyloids in human diseases === To date, 37 human proteins have been found to form amyloid in pathology and be associated with well-defined diseases. The International Society of Amyloidosis classifies amyloid fibrils and their associated diseases based upon associated proteins (for example ATTR is the group of diseases and associated fibrils formed by TTR). A table is included below.
Sources: en.wikipedia.org
The following is a list of fentanyl analogues (sometimes referred to as fentalogs), and includes both compounds developed by pharmaceutical companies for legitimate medical use, and those which have been sold as designer drugs. The latter have been reported to national drug control agencies such as the DEA, and some to transnational agencies such as the EMCDDA and UNODC. This is not a comprehensive or exhaustive list of fentanyl analogues, as more than 1400 compounds from this family have been described in the scientific and patent literature. However, this list does include many notable compounds that have reached late-stage human clinical trials, and compounds which have been sold as designer drugs, as well as representative examples of significant structural variations reported in the scientific and patent literature. The structural variations among fentanyl analogues can impart profound pharmacological differences between each other, especially regarding potency and efficacy. In the United States, the Drug Enforcement Administration (DEA) placed the class of "Fentanyl-Related Substances" on the list of Schedule I drugs in 2018, making it illegal to manufacture, distribute, or possess fentanyl analogs, with very broad terminology being used in its scheduling. Regarding the temporary control of fentanyl-related substances, Schedule I was extended through December 31, 2024 by Public Law 117-328.
genomic DNA (gDNA) Also chromosomal DNA. The DNA contained in chromosomes, as opposed to the extrachromosomal DNA contained in separate structures such as plasmids or organelles such as mitochondria or chloroplasts.
== Cambodian controversy (1970) == The Paris peace talks had become stalemated by late 1969, owing to the obstructionism of the South Vietnamese delegation who wanted the talks to fail. The South Vietnamese President Nguyễn Văn Thiệu did not want the United States to withdraw from Vietnam, and out of frustration with him, Kissinger decided to begin secret peace talks in Paris parallel to the official talks that the South Vietnamese were unaware of. On 21 February 1970, in a modest house in a Paris suburb, Kissinger secretly met Lê Đức Thọ, the North Vietnamese diplomat who was to become his most tenacious adversary. In 1981, Kissinger told the journalist Stanley Karnow: "I don't look back on our meetings with any great joy, yet he was a person of substance and discipline who defended the position he represented with dedication". Not until February 1971 were Rogers and Laird first informed of the parallel peace talks in Paris. Kissinger was to meet Tho three times between February–April 1970, and the North Vietnamese first sensed a softening of the American position during these talks as Kissinger slightly altered the "mutual withdrawal formula" that the Americans had previously held to. Nixon was gravely disappointed that the secret talks in Paris did not have the prompt results he wanted. Kissinger wrote in his memoirs that "historians rarely do justice to the psychological stress on a policy-maker", noting that by early 1970 Nixon was feeling very much besieged and inclined to lash out against a world he was believed was plotting his downfall.
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.